RxDoctor Payments Data

Gabriel Rendon, MD

Gastroenterology · McKinney, TXNPI 1235161761

Payments from drug & device makers

$40,822in general payments, 2019–2025

Across 702 payments — averaging $58.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$30K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Boston Scientific$1K
  • Johnson & Johnson$799
  • Medtronic$782
  • Regeneron Healthcare Solutions, Inc.$710
  • plus $6K from 34 others

What the payments were for

  • Speaking & faculty fees$24,17559%
  • Travel & lodging$9062%
  • Food & beverage$15,65038%
  • Education$610%
  • Other$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,822 in reported general payments places this provider in the 85th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$90,851
Medicare patients
291
Services billed
1,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$327,399
CreonLipase/Protease/Amylase28$142,965
Humira PenAdalimumab14$98,407
LinzessLinaclotide21$24,156
Colesevelam Hcl34$5,426
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag36$4,396
SutabSod Sulf/Pot Chloride/Mag Sulf26$4,297
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C23$3,197
Sucralfate21$3,069
Mesalamine21$2,819
Pantoprazole Sodium107$1,169
CholestyramineCholestyramine (With Sugar)16$1,060
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates14$929
Esomeprazole Magnesium25$868
Omeprazole58$807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$799$327,39912 claims
AbbVieCreon, Linzess$30,207$167,12049 claims
Braintree Laboratories, Inc.Suflave, Sutab$64$8,69362 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$436$3,19723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →